PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Abstract In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as prognostic markers in clear cell renal cell carcinoma. In contrast, little is known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression data were associated with clinicopathological parameters and overall survival (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining intensity. No significant association between clinicopathological parameters and PD-L2 expression was identified. A significant difference between 5- and 10-year OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs. PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis PD-L2 expression failed to be proofed as an independent prognostic factor. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a significant diminished OS in dependence of PD-L2 expression. This implicates that PD-L2 might play a role as prognostic marker in chRCC demanding further evaluation.
PMID
Related Publications

PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?

Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.

c-Met in chromophobe renal cell carcinoma.

The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Authors

Mayor MeshTerms
Keywords

Chromophobe histology

PD-L2

Renal cell carcinoma

Survival

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28353093
OWN - NLM
STAT- MEDLINE
DA  - 20170329
DCOM- 20170407
LR  - 20170407
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
PG  - 71
LID - 10.1007/s12032-017-0926-1 [doi]
AB  - In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely
      studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as 
      prognostic markers in clear cell renal cell carcinoma. In contrast, little is
      known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The
      aim of this study was to evaluate the prevalence, distribution and prognostic
      impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who
      underwent renal surgery due to chRCC were retrospectively evaluated. Tumor
      specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression 
      data were associated with clinicopathological parameters and overall survival
      (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining
      intensity. No significant association between clinicopathological parameters and 
      PD-L2 expression was identified. A significant difference between 5- and 10-year 
      OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs.
      PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis 
      PD-L2 expression failed to be proofed as an independent prognostic factor. In
      conclusion, to our knowledge this is the first study evaluating the prognostic
      impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a
      significant diminished OS in dependence of PD-L2 expression. This implicates that
      PD-L2 might play a role as prognostic marker in chRCC demanding further
      evaluation.
FAU - Erlmeier, Franziska
AU  - Erlmeier F
AD  - Institute of Pathology, Technical University Munich (TUM), Trogerstrasse 18,
      81675, Munich, Germany. [email protected]
AD  - Member of the German Renal Cell Tumor Consortium, Jena, Germany.
      [email protected]
FAU - Weichert, Wilko
AU  - Weichert W
AD  - Institute of Pathology, Technical University Munich (TUM), Trogerstrasse 18,
      81675, Munich, Germany.
AD  - Member of the German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - Autenrieth, Michael
AU  - Autenrieth M
AD  - Department of Urology, Technical University of Munich, Klinikum rechts der Isar, 
      Munich, Germany.
FAU - Wiedemann, Max
AU  - Wiedemann M
AD  - The Munich Cancer Registry of the Tumorzentrum Munich, Institute of Medical
      Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University 
      Munich, Munich, Germany.
FAU - Schrader, Andres Jan
AU  - Schrader AJ
AD  - Member of the German Renal Cell Tumor Consortium, Jena, Germany.
AD  - Clinic for Urology, University Hospital Muenster, Munster, Germany.
FAU - Hartmann, Arndt
AU  - Hartmann A
AD  - Member of the German Renal Cell Tumor Consortium, Jena, Germany.
AD  - Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
FAU - Ivanyi, Philipp
AU  - Ivanyi P
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
      Hannover Medical School, Hannover, Germany.
FAU - Steffens, Sandra
AU  - Steffens S
AD  - Member of the German Renal Cell Tumor Consortium, Jena, Germany.
AD  - Clinic for Urology, University Hospital Muenster, Munster, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170328
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PDCD1LG2 protein, human)
RN  - 0 (Programmed Cell Death 1 Ligand 2 Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*biosynthesis
MH  - Carcinoma, Renal Cell/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Programmed Cell Death 1 Ligand 2 Protein/*biosynthesis
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - Chromophobe histology
OT  - PD-L2
OT  - Renal cell carcinoma
OT  - Survival
EDAT- 2017/03/30 06:00
MHDA- 2017/04/08 06:00
CRDT- 2017/03/30 06:00
PHST- 2017/02/10 [received]
PHST- 2017/03/21 [accepted]
AID - 10.1007/s12032-017-0926-1 [doi]
AID - 10.1007/s12032-017-0926-1 [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>